JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL.
McKenney AS, et al. Among authors: rampal r.
J Clin Invest. 2018 Feb 1;128(2):789-804. doi: 10.1172/JCI94516. Epub 2018 Jan 22.
J Clin Invest. 2018.
PMID: 29355841
Free PMC article.